
ANL Stock Forecast & Price Target
ANL Analyst Ratings
Bulls say
Adlai Nortye is attractive fundamentally because it has two clinically differentiated, high-upside RAS assets: AN9025, a pan-RAS(ON) inhibitor with strong preclinical potency and a Phase 1 readout expected in 1H27, and AN4035, the first pan-RAS(ON) ADC dosed in humans with FDA “Study-May-Proceed” support and first patient dosing in Australia. The company’s strategy targets a large RAS-driven market spanning colorectal, pancreatic, and lung cancers, where systemic RAS inhibition has been constrained by on-target toxicity, and AN4035’s CEACAM5-directed delivery may widen the therapeutic window and improve combinability. Valuation remains asymmetric versus larger peers, with a market cap around $0.7B versus $35B and $3.8B for comparable RAS developers, while the stock had already risen 700% YTD against 10% for XBI.
Bears say
Adlai Nortye is viewed negatively because its lead RAS program, AN9025, still lacks clinical validation despite strong preclinical data, leaving open the possibility that its higher affinity and long half-life could create toxicity that undermines the therapeutic window. The company’s intermittent-dosing thesis remains clinically unproven, and the fact that pan-RAS inhibition also affects healthy tissue raises persistent risks of rash, mucositis, GI toxicity, dose interruptions, and dose reductions that could weaken both efficacy and combination potential. In addition, the panRAS(ON) space is IP-sensitive, so freedom-to-operate uncertainty may limit strategic interest, while the broader pipeline remains early and unproven relative to competitors.
This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.
ANL Analyst Forecast & Price Prediction
Start investing in ANL
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Adlai Nortye Ltd (ANL) Forecast
ANL Analyst Forecast & Price Prediction
Start investing in ANL
Order type
Buy in
Order amount
Est. shares
0 shares